Rewriting Life

From the Labs: Biotechnology

New publications, experiments, and breakthroughs in biotechnology – and what they mean.

A Clue to Living Longer
Growth hormone and insulin may explain why restricting calories boosts longevity

A mouse lacking the ability to respond to growth hormone (right) has a longer life span than a normal mouse (left). (Courtesy of Michael Bonkowski)

SOURCE: “Targeted Disruption of Growth Hormone Receptor Interferes with the Beneficial Actions of Calorie Restriction” M. S. Bonkowski et al.Proceedings of the National Academy of Sciences 103(20): 7901-7905

This story is part of our July/August 2006 Issue
See the rest of the issue
Subscribe

RESULTS: Scientists at the Southern Illinois School of Medicine discovered that mice engineered to be resistant to growth hormone have a longer life span than normal mice; the increase is similar to that seen in normal mice fed a diet low in calories, but engineered mice fed a low-calorie diet showed no additional gain in longevity. Both the engineered mice and the calorie-restricted normal mice were much more sensitive to insulin, suggesting a possible mechanism for the increase in longevity.

WHY IT MATTERS: Scientists have long known that a low-calorie but nutritionally adequate diet can boost longevity in organisms as diverse as yeast, flies, and mice. But they don’t know why. (See “Is Defeating Aging a Dream?”) That the hormone-resistant mice mimic the longevity of calorie-restricted mice is an important clue to the mechanisms responsible for those effects. Scientists hope to one day design drugs that target the underlying biological pathway and thereby increase life span or treat age-related disease without dietary restrictions.

METHODS: The scientists used genetically engineered mice that lacked the receptor for growth hormone. Engineered and normal mice were then fed a normal or a calorie-restricted diet.

NEXT STEPS: The researchers plan to investigate which of the many effects of caloric restriction lead to increased longevity. They will also test the hypothesis that insulin sensitivity is an important determinant of life span.

Microbial Drug Factories
Synthetically engineered micro-örganisms could provide a cheap way to manufacture drugs

SOURCE: “Production of the Antimalarial Drug Precursor Artemisinic Acid in Engineered Yeast” D. K. Ro et al.Nature 440(7086): 940-943

RESULTS: Dae-Kyun Ro, Jay Keasling (who wrote a “Notebook” entry), and colleagues at the University of California, Berkeley, have genetically engineered yeast to produce large quantities of artemisinic acid, a precursor to the malaria drug artemisinin.

WHY IT MATTERS: Artemisinin combination therapies are an effective treatment for malaria. But the drugs, which are derived from the sweet wormwood tree, are expensive and in short supply. More-efficient manufacturing methods could reduce the cost of the malaria drugs to the point that a larger number of people in poor countries could afford them. The work also illustrates the great potential of synthetic biology – the attempt to design and create organisms to perform specific functions.

METHODS: The researchers re-designed the metabolic pathways of yeast to more efficiently make an artemisinin precursor called amorphadiene, which plants naturally make in small quantities. Using a newly identified wormwood gene, they further engineered the yeast to complete the last few steps of the synthesis process to create artemisinic acid.

NEXT STEPS: Keasling’s team will continue to fine-tune the system to make it even more efficient and therefore more cost effective. It will also scale up the manufacturing process in collaboration with Amyris Biotechnologies, a company in Emeryville, CA, that was founded to commercialize the technology.

From the Labs: Nanotechnology
From the Labs: Information Technology

The latest Insider Conversation is live! Listen to the story behind the story.

Subscribe today
Already a Premium subscriber? Log in.

Uh oh–you've read all of your free articles for this month.

Insider Premium
$179.95/yr US PRICE

More from Rewriting Life

Reprogramming our bodies to make us healthier.

Want more award-winning journalism? Subscribe and become an Insider.
  • Insider Premium {! insider.prices.premium !}*

    {! insider.display.menuOptionsLabel !}

    Our award winning magazine, unlimited access to our story archive, special discounts to MIT Technology Review Events, and exclusive content.

    See details+

    What's Included

    Bimonthly home delivery and unlimited 24/7 access to MIT Technology Review’s website.

    The Download. Our daily newsletter of what's important in technology and innovation.

    Access to the Magazine archive. Over 24,000 articles going back to 1899 at your fingertips.

    Special Discounts to select partner offerings

    Discount to MIT Technology Review events

    Ad-free web experience

    First Look. Exclusive early access to stories.

    Insider Conversations. Listen in as our editors talk to innovators from around the world.

  • Insider Plus {! insider.prices.plus !}* Best Value

    {! insider.display.menuOptionsLabel !}

    Everything included in Insider Basic, plus ad-free web experience, select discounts to partner offerings and MIT Technology Review events

    See details+

    What's Included

    Bimonthly home delivery and unlimited 24/7 access to MIT Technology Review’s website.

    The Download. Our daily newsletter of what's important in technology and innovation.

    Access to the Magazine archive. Over 24,000 articles going back to 1899 at your fingertips.

    Special Discounts to select partner offerings

    Discount to MIT Technology Review events

    Ad-free web experience

  • Insider Basic {! insider.prices.basic !}*

    {! insider.display.menuOptionsLabel !}

    Six issues of our award winning magazine and daily delivery of The Download, our newsletter of what’s important in technology and innovation.

    See details+

    What's Included

    Bimonthly home delivery and unlimited 24/7 access to MIT Technology Review’s website.

    The Download. Our daily newsletter of what's important in technology and innovation.

/
You've read all of your free articles this month. This is your last free article this month. You've read of free articles this month. or  for unlimited online access.